S Gangi, L Bergantini, P Cameli, I Paggi, M Spalletti… - Biomedicines, 2024
… The expression of PD-1 and TIGIT was abundant on T and NK cell subsets of the two lung fibrotic groups, IPF … of pulmonaryfibrosis, idiopathic and secondary to SARS-CoV-2 infection. We observed a significant imbalance not only in CD4, CD8 …
S Iftikhar, SF Alhaddad, CN Paulsingh, MF Riaz… - Cureus, 2024
… As the global incidence of idiopathicpulmonaryfibrosis (IPF) is on the rise, … ) in IPF and answers the question, “Does proton pump inhibitor improve only the prognosis of gastroesophageal associated idiopathicpulmonaryfibrosis or for other …
S Gangi, L Bergantini, P Cameli, I Paggi, M Spalletti… - Biomedicines, 2024
… The expression of PD-1 and TIGIT was abundant on T and NK cell subsets of the two lung fibrotic groups, IPF … of pulmonaryfibrosis, idiopathic and secondary to SARS-CoV-2 infection. We observed a significant imbalance not only in CD4, CD8 …
L Zhu, Y Xu, J Wang, Y Zhang, J Zhou, H Wu - Molecular Genetics and Genomics, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic pulmonaryfibrosis disease that is fatal. Mesenchymal stem cells (MSCs)-secreted … IPFwho underwent pulmonary transplantation. This suggests that miR-30b plays an important role in both the …
X Zhang, L Jia, R Hou, Y Zhao, L Zhang, X Tong, Y Mo… - bioRxiv, 2024
… for IdiopathicPulmonaryFibrosis (IPF) and non- 2 IPFprogressive fibrotic interstitial lung diseases (non-IPF-PF) highlights the need for 3 identifying common therapeutic targets. We utilize single-cell RNA sequencing data 4 from six disease …
H Lian, R Wan, K Yang, S Ma, Y Wang, K Xu, L Cheng… - 2024
… Idiopathic pulmonary brosis (IPF) is a progressive and fatal interstitial lung disease with poor therapeutic options while the pathogenesis keeps elusive. Herein we demonstrated that the expression of FASN was increased in broblasts of IPF …
A Bahramifar, RM Jafari, M Sheibani, MA Manavi… - Tissue and Cell, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a fibrotic lung condition that produces symptoms including coughing which may cause by excessive … of serotonin, playing a pivotal role in regulating both inflammation and oxidative stress which is …
… the usage of statin therapy in lung diseases like idiopathicpulmonaryfibrosis (IPF) (Richeldi et al. Citation2014; Kang et al. Citation2021). … evidence to conclude the effect of statin therapy on disease-related outcomes in IPF (Kim et al. Citation2021 …
P Scrivani, T Schwarz, T Liuti - BSAVA Manual of Canine and Feline Thoracic …, 2024
… High-resolution dorsal thoracic CT image through the dorsal part of the lungs of a 13-year-old West Highland White Terrier with idiopathicpulmonaryfibrosis. In the cranial aspect of the left lung, there is a small (4 mm) soft tissue nodule (arrowed) …
W Gan, W Song, Y Gao, X Zheng, F Wang, Z Zhang… - Journal of Translational …, 2024
… circRNAs in idiopathicpulmonaryfibrosis(IPF). Therefore, identifying the differentially-expressed exosomal circRNAs in IPF could provide … prediction in patients with IPF. Initially, we investigated the expression profile of circRNAs in …
M Drent, PA Wijnen, NT Jessurun, AM Harmsze… - Drug Safety, 2024
… The causes of fibrotic ILD vary from identifiable causes, including autoimmune or exposure-related causes, to those classified as idiopathic, ie., idiopathic interstitial pneumonias [1]. The pathological pattern, usual interstitial pneumonia or idiopathic …
… This study provides a detailed analysis of IdiopathicPulmonaryFibrosis, identifying 459 key genes and pathways using advanced bioinformatics and statistical methods. It 460 emphasizes the importance of immune cells and genetic …
HY Yoon, SY Kim, JW Song - European Respiratory Journal, 2024
… of idiopathicpulmonaryfibrosis (IPF) with a poor prognosis. However, the association between individual exposure to air pollutants and lung cancer development in patients with IPF is … Idiopathicpulmonaryfibrosis (IPF) is a chronic …
P Spagnolo, TM Maher - American Journal of Respiratory and Critical Care …, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a relentlessly progressive fibrotic lung disease of unknown origin associated with high morbidity, … systems biology of pulmonaryfibrosis, the inefficiency of current IPF trial design and endpoints and the …
J Cao, Y Ma, W Zhao, C Feng - BMC Pulmonary Medicine, 2024
… Sex difference in the incidence rate of idiopathicpulmonaryfibrosis (IPF) indicates that estrogen has a certain protective effect on the … , and IPF. Our study intended to employ Mendelian randomization (MR) method to elucidate the causal …
… : Idiopathicpulmonaryfibrosis (IPF) is a chronic fibroproliferative disease characterised by accumulation of scar tissue within the lung parenchyma. The clinical course of IPF … IdiopathicPulmonaryfibrosis (IPF) is a chronic progressive …
N Chaudhuri, P Spagnolo, C Valenzuela, VC Amatto… - 2024
… Idiopathic pulmonary brosis (IPF), the archetypal progressive brosing ILD (PF-ILD) and the most common idiopathic interstitial pneumonia, … Approximately one third of patients with brosing ILDs other than IPF may experience disease progression, de …
M Rezaee, N Azizi, B Danaei, A Davari… - The International Journal of …, 2024
… In the subgroup analysis, the TB rate among patients with silicosis and idiopathicpulmonaryfibrosis (IPF) was respectively 35.6% (95% CI … studies with idiopathicpulmonaryfibrosis(IPF).The remaining three articles described patients with …
K Takehara, Y Koga, Y Hachisu, M Utsugi, Y Sawada… - Respiratory Investigation, 2024
… The antifibrotic agents pirfenidone and nintedanib have been shown to be effective in patients with idiopathicpulmonaryfibrosis(IPF). However, discontinuation of antifibrotic drugs is a major clinical concern because of the lack of …
N WEI, X Fang, X Zhao, F Zeng, C Yu, NTT Huyen, F Li… - 2024
… Current hot research topics mainly include FPS-relevant diseases (interstitial lung disease, idiopathicpulmonaryfibrosis and pulmonaryfibrosis), complications (pulmonary hypertension, chronic obstructive pulmonary disease, and lung cancer), commonly …
JY Lee, NS Reyes, S Ravishankar, M Zhou… - The Journal of Clinical …, 2024
… fibroblasts isolated from patients with idiopathicpulmonaryfibrosis (IPF), and reduced 13 p16INK4a+ fibroblasts from IPFPCLS ex vivo. This study provides proof of concept for a 14 … histologic evidence of p16INK4a+ cells in IPF and animal …
in vivo スクリーニングプラットフォームは、肺線維症における p16 INK4a+ 線維芽細胞を標的とする老化細胞破壊化合物を特定
インスリン抵抗性は、タイプ2糖尿病の特徴であり、全身性炎症と酸化ストレスを促進することでILDの発症に寄与する可能性があります。これらの状態は、多くの形態のILDの特徴である肺線維症につながることができます。糖尿病におけるプロ炎症性サイトカインの上昇レベルは、肺炎症と線維症を悪化させる可能性があります(Raghu et al., 2011; American Journal of Respiratory and Critical Care Medicine)。
高度グリケーション最終産物(AGEs)
AGEsは、タンパク質や脂質が糖と反応することによって形成される化合物で、糖尿病の人ではさまざまな組織に蓄積することがあります。これらの化合物は、肺における炎症と線維症を促進することができ、ILDの病態形成に寄与する可能性があります(Queenan et al., 2012; Diabetes Care)。
疫学的証拠
いくつかの疫学研究では、一般人口と比較して糖尿病の人におけるILDの有病率が高いことが観察されています。例えば、糖尿病はILDの発症の独立したリスクファクターであることを示すコホート研究があり、これら2つの状態間に重要なリンクがあることを示唆しています(Garcia-Sancho Figueroa et al., 2010; European Respiratory Journal)。
ILDと糖尿病の両方を持つ患者の管理には、両方の状態に対処する包括的なアプローチが必要です。抗線維化剤であるピルフェニドンとニンテダニブは、ILDの進行を遅らせることが示されており、糖尿病における血糖コントロールは、全身性炎症とAGEsの形成を最小限に抑えるために重要です。生活習慣の変更、特に食事と運動は、両方の状態を管理するために重要です(King Jr et al., 2014; New England Journal of Medicine)。
Raghu, G., Collard, H. R., Egan, J. J., et al. (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 183(6), 788-824.
Queenan, K. J., Stewart, M. J., Smith, E. P., et al. (2012). Advanced glycation end products and their receptors co-localize in rat organs susceptible to diabetic microvascular injury. Diabetes Care, 35(4), 883-891.
Garcia-Sancho Figueroa, M. C., Carrillo, G., Pérez-Padilla, R., et al. (2010). Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. European Respiratory Journal, 35(2), 440-445.
King Jr, T. E., Bradford, W. Z., Castro-Bernardini, S., et al. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2083-2092.